Results of Autologous Transplantation for CML After In Vivo Purging
| Study . | In Vivo Purging . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Chemotherapy . | Patients Studied . | Cytogenetic . | Autologous Transplantation . | ||||||
| . | Regimen . | . | Response . | Patients Transplanted . | Stem Cell Source . | Cytogenetic Response . | Survival (mo) . | . | ||
| . | . | . | CR . | PR (%Ph−) . | . | . | CR . | PR (%Ph−) . | . | . |
| Carella48 (Genoa) | ICE | 46 | 17 | 6 (>50%) | 16 | PB | 5 | NA | 15-29 | |
| Talpaz49 (MD Anderson) | DC/FMC/ICE | 21 | 3 | 7 (30-92%) | 21 | PB/BM | 5 | 5 (26-90%) | 1-21 | |
| McGlave (Minnesota) | Cy | 15 | 0 (BM) | 1 (BM) | 15 | BM | 2 | 3 | 12-26 | |
| 1 (PB) | 4 (PB) | |||||||||
| MACy | 13 | 1 (PB) | 6 (>66%) | 9 | PB | 0 | 3 | 2-12 | ||
| Tringali50 (Palermo) | Cy | 6 | 0 | 1 (NA) | 6 | PB/BM | 1 | 1 (>60%) | 14-26 | |
| O'Brien51 (Hammersmith) | ICE | 9 | NA | NA | 6 | PB | 0 | 3 (NA) | 0.6-11 | |
| Chalmers52 (Glasgow) | I, C | 25 | 11 | 2 (>50%) | 8 | PB | 1 | 1 (>50%) | NA | |
| Durrant53 (Australia) | ICE | 15 | 3 | 4 (>65%) | 5 | PB | 4 | NA | NA | |
| Sureda54 (Barcelona) | ICE | 3 | 1 | 1 (>33%) | 2 | PB | NA | NA | NA | |
| Simonsson55 (Sweden) | Hu/Ifn, DC MEA, AmA | 97 | 23 | NA | 18 | BM | 13 | 2 (>65%) | 13-32 | |
| Study . | In Vivo Purging . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Chemotherapy . | Patients Studied . | Cytogenetic . | Autologous Transplantation . | ||||||
| . | Regimen . | . | Response . | Patients Transplanted . | Stem Cell Source . | Cytogenetic Response . | Survival (mo) . | . | ||
| . | . | . | CR . | PR (%Ph−) . | . | . | CR . | PR (%Ph−) . | . | . |
| Carella48 (Genoa) | ICE | 46 | 17 | 6 (>50%) | 16 | PB | 5 | NA | 15-29 | |
| Talpaz49 (MD Anderson) | DC/FMC/ICE | 21 | 3 | 7 (30-92%) | 21 | PB/BM | 5 | 5 (26-90%) | 1-21 | |
| McGlave (Minnesota) | Cy | 15 | 0 (BM) | 1 (BM) | 15 | BM | 2 | 3 | 12-26 | |
| 1 (PB) | 4 (PB) | |||||||||
| MACy | 13 | 1 (PB) | 6 (>66%) | 9 | PB | 0 | 3 | 2-12 | ||
| Tringali50 (Palermo) | Cy | 6 | 0 | 1 (NA) | 6 | PB/BM | 1 | 1 (>60%) | 14-26 | |
| O'Brien51 (Hammersmith) | ICE | 9 | NA | NA | 6 | PB | 0 | 3 (NA) | 0.6-11 | |
| Chalmers52 (Glasgow) | I, C | 25 | 11 | 2 (>50%) | 8 | PB | 1 | 1 (>50%) | NA | |
| Durrant53 (Australia) | ICE | 15 | 3 | 4 (>65%) | 5 | PB | 4 | NA | NA | |
| Sureda54 (Barcelona) | ICE | 3 | 1 | 1 (>33%) | 2 | PB | NA | NA | NA | |
| Simonsson55 (Sweden) | Hu/Ifn, DC MEA, AmA | 97 | 23 | NA | 18 | BM | 13 | 2 (>65%) | 13-32 | |
Abbreviations: CP, chronic phase; AP, accelerated phase; BC, blast crisis; I, Idarubicin; C, ARA-C; E, Etposide; D, Daunorubicin; F, Fludarabine; M, Mitoxantrone; Hu, Hydroxyurea; Ifn, IFN-α; Am, Amsacrine; Ara-C; Cy, high-dose Cytoxan.